Physician profile
Grace K Schultz
NPI 1154879666
$1,453.26
in general payments reported to CMS, 2019-2025
17 companies · $823 in 2025
The $823 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.36 · 2022: $30.33 · 2023: $92.57 · 2024: $470 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.57 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $319.36 | 2024-2025 | Farapulse, Emblem Mri S-Icd |
| Biotronik INC. | $233.70 | 2025 | Solia, Amvia Edge, Acticor 7 Vr-T Dx |
| Abbott Laboratories | $156.07 | 2025 | Ensite |
| Medtronic, INC. | $134.25 | 2023-2025 | Affera Mapping System |
| Janssen Pharmaceuticals, INC | $99.65 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $96.63 | 2023-2024 | Farxiga, Wainua, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.98 | 2023-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $66.93 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $60.71 | 2024-2025 | Verquvo |
| Novo Nordisk INC | $45.35 | 2024-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $38.84 | 2024-2025 | Eliquis |
| Pfizer INC. | $32.72 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $22.31 | 2024 | Evkeeza |
| Actelion Pharmaceuticals US, INC. | $17.58 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.35 | 2024 | Jardiance |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $16.43 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $16.40 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.